A new report, “What’s Hot and Key Trends in Medtech in 2013,” is now available by healthcare corporate finance and strategy specialist Results Healthcare.
Authored by Results Healthcare Managing Director, Kevin Bottomley, the report takes an in-depth look at a market which is predicted to grow at 4.4% (CAGR) over 2011-2018 to reach a value of $440B by 2018,* in contract to the Rx market, which is forecast to grow at only 2.5% over the same period. The report indicates that In vitro diagnostics will be the largest Medtech segment, with an estimated value of £55B by 2018, with key sub-segment areas for growth identified as renal denervation, robotic-assisted surgery, mobile health, Transcatheter Valve Replacements, Left Ventricular Assist Devices, cervical disc replacements, molecular diagnostics, diagnostic imaging services and intraocular lenses.
The report cites major drivers for growth as an aging population and an increase in chronic disease coupled with the emerging markets’ ability to pay for Medtech. Key trends include the need for products that can continuously monitor the patient, preferably at home, while minimally invasive technologies are also experiencing rapid growth.
“The need for more efficient, effective, and overall economically beneficial healthcare is increasing,” Bottomley comments. “Companies that can show that their products perform better than their competitors, improve patient outcome or save the healthcare system money are more likely to win reimbursement, plus the companies themselves are more likely to attract investment.”
Other factors examined in the report include the increasing importance of generics, the market outlook, the M&A landscape and legislative and regulatory issues.
The full report is available to download free at Results Healthcare’s new website.
*Evaluate MedTech